Genetic Signatures Limited (GSS) Q4 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen, and welcome to this morning's webinar. My name is Maria Halas, and I am the CEO of Genetic Signatures. With me today is Angie Wang, who is our head of finance, and Angie is joining us for the first time. She has recently been promoted, and this is her first annual audit and financial results release. and the fact that she became quite ill recently right after we released the result has nothing to do with the stress that she may have been under during the course of the audit. With that in mind, I would like to just note the order for the day. The order will be that I'll make a short presentation on the actual results, following which we will open up for questions and you'll be able to ask. We have had some questions that have been submitted prior to the meeting and I will start by answering those questions and then open it for the forum. Obviously today's topic is the financial results for the 2026 financial year. What we'll be talking about is really first I just want to recap on about genetic signatures and the Real advantages all around the company's assets, our product portfolio, and generally where we sit on the market. I will talk a little bit about the highlights from the financial year, the actual results, some of the key things that we've achieved since I've started in March this year, including the progress we've made on the growth strategy that we've announced on the 10th of June. Finally, I'll talk through some of the outlook and some of what Just to recap, we are a respiratory and enteric multiplex PCR solution provider. In addition to these product portfolios, we have molecular diagnostics, and those will be either regulatory approved by the TGA, FDA or CE mark. We also have a research use only products. We manufacture...